An ongoing dialogue on HIV/AIDS, infectious diseases,
July 26th, 2023
REPRIEVE Trial Highlights Shift in HIV Care from ID to General Medicine
The biggest news this week at the 12th IAS Conference on HIV Science here in Brisbane, Australia, was the results of REPRIEVE, a large randomized clinical trial conducted in people with HIV. It’s not a study of novel antiretroviral regimens, or of treatment or prevention of opportunistic infections, or of an HIV eradication strategy using […]
Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
NEJM Journal Watch — Recent Infectious Disease Articles- How Serious Is Artemisinin Partial Resistance in African Malaria Parasites?
- Observations from ID and Beyond: Who's Going to Get Lenacapavir for HIV Prevention?
- Can We Shorten the Duration of Antibiotic Treatment for Bacteremia?
- Rifampin and Gentamicin for Staphylococcal Prosthetic Valve Endocarditis: Strictly Necessary?
- Gauging Risk for Liver Cancer: Hepatitis B Viral Load Might Be a Clue